{"id":"prednisone-therapy-and-pharmacokinetic","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Hyperglycemia"},{"rate":"5-20","effect":"Hypertension"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-15","effect":"Mood changes (anxiety, irritability)"},{"rate":"30-50","effect":"Osteoporosis (chronic use)"},{"rate":"variable","effect":"Immunosuppression/increased infection risk"},{"rate":"5-10","effect":"Gastrointestinal upset"},{"rate":"10-20","effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. It decreases production of cytokines (IL-1, IL-6, TNF-α), reduces immune cell activation and proliferation, and stabilizes lysosomal membranes to prevent release of inflammatory enzymes. These effects make it effective across multiple inflammatory and autoimmune conditions.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:30.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Adrenal insufficiency"},{"name":"Certain hematologic malignancies and lymphomas"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT04647526","phase":"PHASE3","title":"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","startDate":"2021-02-25","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":455},{"nctId":"NCT00290667","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2004-02","conditions":"Lymphoma","enrollment":586},{"nctId":"NCT00466440","phase":"PHASE2","title":"A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-06","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT04243434","phase":"PHASE1","title":"PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients","status":"UNKNOWN","sponsor":"Acrotech Biopharma Inc.","startDate":"2020-08-15","conditions":"Hematologic Diseases","enrollment":56},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01400464","phase":"PHASE4","title":"Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2009-07","conditions":"Giant Cell Arteritis","enrollment":150},{"nctId":"NCT00137436","phase":"PHASE1, PHASE2","title":"Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-10","conditions":"Prostatic Neoplasms","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prednisone therapy and pharmacokinetic","genericName":"Prednisone therapy and pharmacokinetic","companyName":"University Hospital, Caen","companyId":"university-hospital-caen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}